Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Publication ,  Journal Article
Cohen, YZ; Butler, AL; Millard, K; Witmer-Pack, M; Levin, R; Unson-O'Brien, C; Patel, R; Shimeliovich, I; Lorenzi, JCC; Horowitz, J; Walsh, SR ...
Published in: Plos One
2019

BACKGROUND: Additional forms of pre-exposure prophylaxis are needed to prevent HIV-1 infection. 3BNC117 and 10-1074 are broadly neutralizing anti-HIV-1 antibodies that target non-overlapping epitopes on the HIV-1 envelope. We investigated the safety, tolerability, pharmacokinetics, and immunogenicity of the intravenous administration of the combination of 3BNC117 and 10-1074 in healthy adults. METHODS: This randomized, double-blind, placebo-controlled, single center, phase 1 study enrolled healthy adults aged 18-65 years to receive one infusion of 3BNC117 immediately followed by 10-1074 at 10 mg/kg, three infusions of 3BNC117 followed by 10-1074 at 3 mg/kg or 10 mg/kg every 8 weeks, or placebo infusions. The primary outcomes were safety and pharmacokinetics. This trial is registered with ClinicalTrials.gov, number NCT02824536. FINDINGS: Twenty-four participants were enrolled in a 3:1 ratio to receive the study products or placebo. The combination of 3BNC117 and 10-1074 was safe and generally well tolerated. There were no serious adverse events considered related to the infusions. The mean elimination half-lives of 3BNC117 and 10-1074 were 16.4 ± 4.6 days and 23.0 ± 5.4 days, respectively, similar to what was observed in previous studies in which each antibody was administered alone. Anti-drug antibody responses were rare and without evidence of related adverse events or impact on elimination kinetics. INTERPRETATION: Single and repeated doses of the combination of 3BNC117 and 10-1074 were well tolerated in healthy adults. These data support the further development of the combination of 3BNC117 and 10-1074 as a long-acting injectable form of pre-exposure prophylaxis for the prevention of HIV-1 infection.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Plos One

DOI

EISSN

1932-6203

Publication Date

2019

Volume

14

Issue

8

Start / End Page

e0219142

Location

United States

Related Subject Headings

  • Pre-Exposure Prophylaxis
  • Placebo Effect
  • Male
  • Humans
  • Healthy Volunteers
  • HIV-1
  • HIV Seropositivity
  • HIV Infections
  • HIV Antibodies
  • General Science & Technology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cohen, Y. Z., Butler, A. L., Millard, K., Witmer-Pack, M., Levin, R., Unson-O’Brien, C., … Caskey, M. (2019). Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. Plos One, 14(8), e0219142. https://doi.org/10.1371/journal.pone.0219142
Cohen, Yehuda Z., Allison L. Butler, Katrina Millard, Maggi Witmer-Pack, Rebeka Levin, Cecilia Unson-O’Brien, Roshni Patel, et al. “Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.Plos One 14, no. 8 (2019): e0219142. https://doi.org/10.1371/journal.pone.0219142.
Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O’Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, Bennett C, Mayer B, Seaton KE, Yates NL, Baden LR, deCamp AC, Ackerman ME, Seaman MS, Tomaras GD, Nussenzweig MC, Caskey M. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. Plos One. 2019;14(8):e0219142.

Published In

Plos One

DOI

EISSN

1932-6203

Publication Date

2019

Volume

14

Issue

8

Start / End Page

e0219142

Location

United States

Related Subject Headings

  • Pre-Exposure Prophylaxis
  • Placebo Effect
  • Male
  • Humans
  • Healthy Volunteers
  • HIV-1
  • HIV Seropositivity
  • HIV Infections
  • HIV Antibodies
  • General Science & Technology